We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Eyeing Pharmacogenetics as Solution to Adverse Events, Lengthy Trials
Industry Eyeing Pharmacogenetics as Solution to Adverse Events, Lengthy Trials
September 27, 2005
When FDA Associate Commissioner Janet Woodcock advocated researching the potential of pharmacogenetics — the study of genetically determined variations in response to specific pharmaceuticals — more than four years ago, most drug companies responded that such research was “too risky.”